November 5, 2021

Notable Analyst Upgrades and Downgrades for Week of November 1 2021 (Part 1)

 



Upgrades:

 


Intel (NASDAQ:INTC) was upgraded by analysts at Northland Securities from an “underperform” rating to a “market perform” rating in a research note issued on Monday, PriceTargets.com reports. The firm presently has a $49.00 price target on the chip maker’s stock. Northland Securities’ price target indicates a potential downside of 0.39% from the company’s current price.

A number of other equities research analysts also recently commented on INTC. The Goldman Sachs Group restated a “sell” rating and issued a $44.00 target price (down previously from $51.00) on shares of Intel in a research report on Friday, October 22nd. Zacks Investment Research upgraded Intel from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Friday, July 9th. Citigroup reduced their target price on Intel from $57.00 to $52.00 and set a “neutral” rating on the stock in a research report on Friday, October 22nd. Credit Suisse Group set a $80.00 price objective on Intel in a report on Friday, October 22nd. Finally, Bank of America cut their price objective on Intel from $52.00 to $45.00 and set an “underperform” rating on the stock in a report on Friday, October 22nd. Eleven equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $56.52. Read more …

 


Merck & Co., Inc. (NYSE:MRK) was upgraded by equities researchers at Argus from a “hold” rating to a “buy” rating in a note issued to investors on Monday, Analyst Price Targets reports. The brokerage presently has a $110.00 price objective on the stock. Argus’ price objective would suggest a potential upside of 25.40% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Morgan Stanley lifted their price objective on Merck & Co., Inc. from $88.00 to $90.00 and gave the stock an “equal weight” rating in a report on Friday. Barclays lifted their price objective on Merck & Co., Inc. from $87.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, October 8th. Truist began coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They set a “buy” rating and a $92.00 price target for the company. Berenberg Bank reissued a “hold” rating and set a $92.00 price target (up previously from $86.00) on shares of Merck & Co., Inc. in a research report on Sunday, October 10th. Finally, Zacks Investment Research raised Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price target for the company in a research report on Tuesday, August 24th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Buy” and an average target price of $94.16. Read more …

 


Starbucks (NASDAQ:SBUX) was upgraded by research analysts at Stephens from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Monday, The Fly reports. The firm currently has a $130.00 price objective on the coffee company’s stock, up from their previous price objective of $118.00. Stephens’ price objective indicates a potential upside of 22.56% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the stock. Piper Sandler boosted their price objective on shares of Starbucks from $104.00 to $108.00 and gave the stock a “neutral” rating in a report on Wednesday, July 28th. Bank of America assumed coverage on shares of Starbucks in a report on Monday, October 11th. They issued a “buy” rating and a $135.00 price objective for the company. Robert W. Baird lowered their price objective on shares of Starbucks from $144.00 to $128.00 and set an “outperform” rating for the company in a report on Friday. UBS Group lowered their price objective on shares of Starbucks from $125.00 to $115.00 and set a “neutral” rating for the company in a report on Friday. Finally, Atlantic Securities downgraded shares of Starbucks from an “overweight” rating to a “neutral” rating and set a $105.00 target price on the stock. in a research note on Thursday, September 30th. Nine analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $123.00. Read more …

 

 


Sanofi (NASDAQ:SNY) was upgraded by stock analysts at HSBC from a “hold” rating to a “buy” rating in a report released on Monday, The Fly reports.

Several other brokerages have also issued reports on SNY. UBS Group reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, August 12th. Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research note on Friday, August 6th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a research note on Wednesday, September 29th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Sanofi in a research note on Thursday, October 14th. Finally, SVB Leerink upgraded shares of Sanofi from a “market perform” rating to an “outperform” rating in a research note on Monday, September 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $51.00. Read more …

 


Unilever (NYSE:UL) was upgraded by Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued to investors on Monday, Price Targets.com reports.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. downgraded shares of Unilever from a “neutral” rating to an “underweight” rating in a report on Thursday, September 2nd. Zacks Investment Research cut shares of Unilever from a “hold” rating to a “sell” rating in a research report on Tuesday, September 7th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Unilever from a “buy” rating to a “hold” rating in a research report on Thursday, September 16th. Three research analysts have rated the stock with a sell rating and two have given a hold rating to the company’s stock. Based on data from MarketBeat.com, Unilever has a consensus rating of “Sell” and an average price target of $61.51. Read more …

 


Franklin Resources (NYSE:BEN) was upgraded by Citigroup from a "neutral" rating to a "buy" rating in a research note issued to investors on Tuesday, Briefing.com reports. The firm presently has a $43.00 price target on the closed-end fund's stock, up from their prior price target of $32.50. Citigroup's target price points to a potential upside of 15.00% from the company's previous close.

Separately, Keefe, Bruyette & Woods raised shares of Franklin Resources from a "market perform" rating to an "outperform" rating in a report on Tuesday. Four analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Franklin Resources currently has a consensus rating of "Hold" and an average price target of $29.11.

Shares of Franklin Resources stock traded up $2.24 on Tuesday, reaching $37.39. The company's stock had a trading volume of 181,746 shares, compared to its average volume of 3,049,427. The company has a market capitalization of $18.80 billion, a price-to-earnings ratio of 15.45 and a beta of 1.22. The company has a quick ratio of 2.14, a current ratio of 2.14 and a debt-to-equity ratio of 0.58. Franklin Resources has a 52 week low of $18.95 and a 52 week high of $36.20. The firm's fifty day simple moving average is $31.06 and its two-hundred day simple moving average is $31.71. Read more …

 

 


ABB (NYSE:ABB) was upgraded by Jefferies Financial Group from an "underperform" rating to a "hold" rating in a report released on Wednesday, The Fly reports.

Several other equities research analysts also recently weighed in on the company. JPMorgan Chase & Co. restated a "neutral" rating on shares of ABB in a report on Friday, October 1st. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of ABB in a research report on Tuesday, July 27th. Exane BNP Paribas raised ABB to a "neutral" rating and set a CHF 37 price objective for the company in a research note on Tuesday, September 21st. UBS Group reissued a "buy" rating on shares of ABB in a research note on Friday, October 22nd. Finally, Morgan Stanley reaffirmed an "underweight" rating on shares of ABB in a research note on Friday, October 22nd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $35.88.

Shares of NYSE:ABB opened at $33.81 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.14 and a quick ratio of 0.85. The business's 50 day moving average price is $34.90 and its 200-day moving average price is $34.89. The firm has a market capitalization of $69.42 billion, a PE ratio of 37.57, a P/E/G ratio of 3.54 and a beta of 1.01. ABB has a 1 year low of $25.24 and a 1 year high of $38.03. Read more …

 


Anheuser-Busch InBev SA/NV (NYSE:BUD) was upgraded by Bank of America from an "underperform" rating to a "neutral" rating in a report released on Wednesday, The Fly reports.

BUD has been the topic of several other research reports. Argus cut Anheuser-Busch InBev SA/NV from a "buy" rating to a "hold" rating in a research report on Thursday, September 30th. Barclays restated an "overweight" rating on shares of Anheuser-Busch InBev SA/NV in a research report on Friday, October 29th. Credit Suisse Group reaffirmed a "neutral" rating on shares of Anheuser-Busch InBev SA/NV in a research note on Wednesday, October 6th. Zacks Investment Research lowered Anheuser-Busch InBev SA/NV from a "hold" rating to a "sell" rating and set a $67.00 price objective on the stock. in a research note on Monday, August 2nd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating on shares of Anheuser-Busch InBev SA/NV in a research note on Friday, October 29th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $72.40. Read more …

 

 

Downgrades:

 


American States Water (NYSE:AWR) was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports.

A number of other research analysts have also commented on AWR. Barclays assumed coverage on shares of American States Water in a research note on Thursday, July 15th. They issued an “equal weight” rating and a $87.00 price target on the stock. Zacks Investment Research downgraded shares of American States Water from a “buy” rating to a “hold” rating and set a $93.00 price objective for the company. in a report on Tuesday, September 14th.

Shares of AWR opened at $90.84 on Monday. American States Water has a 52 week low of $70.07 and a 52 week high of $94.96. The firm has a market cap of $3.35 billion, a P/E ratio of 36.34 and a beta of 0.09. The firm’s 50-day simple moving average is $89.53 and its 200 day simple moving average is $85.01. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.15 and a current ratio of 1.22. Read more …

 

 


Bank of America (NYSE:BAC) was downgraded by stock analysts at Robert W. Baird from a “neutral” rating to an “underperform” rating in a report released on Monday, PriceTargets.com reports. They presently have a $42.00 price objective on the financial services provider’s stock, down from their prior price objective of $47.17. Robert W. Baird’s target price would indicate a potential downside of 12.59% from the stock’s current price. The analysts noted that the move was a valuation call.

Several other equities research analysts have also recently weighed in on the company. Keefe, Bruyette & Woods assumed coverage on Bank of America in a research note on Wednesday, July 7th. They set a “market perform” rating and a $43.87 target price for the company. Jefferies Financial Group upped their price target on shares of Bank of America from $41.00 to $48.00 and gave the stock a “hold” rating in a report on Monday, October 11th. Morgan Stanley upped their price target on shares of Bank of America from $38.00 to $42.00 and gave the stock an “underweight” rating in a report on Thursday, July 29th. Credit Suisse Group upped their price target on shares of Bank of America from $46.00 to $47.00 and gave the stock an “outperform” rating in a report on Friday, July 16th. Finally, Barclays upped their price target on shares of Bank of America from $45.00 to $49.00 and gave the stock an “overweight” rating in a report on Friday, October 15th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $44.04. Read more …

 


Bristol-Myers Squibb (NYSE:BMY) was downgraded by equities researchers at Argus from a “buy” rating to a “hold” rating in a research note issued on Monday, The Fly reports.

A number of other equities analysts have also recently issued reports on BMY. Truist assumed coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, July 28th. They set a “buy” rating and a $74.00 price objective for the company. Barclays lowered their price objective on shares of Bristol-Myers Squibb from $68.00 to $66.00 and set an “equal weight” rating for the company in a research report on Thursday. Berenberg Bank decreased their price target on shares of Bristol-Myers Squibb from $75.00 to $71.00 and set a “buy” rating for the company in a research report on Monday, October 11th. Morgan Stanley decreased their price target on shares of Bristol-Myers Squibb from $71.00 to $66.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 12th. Finally, Truist Securities started coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, July 28th. They issued a “buy” rating and a $74.00 price target for the company. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $71.90. Read more …

 


Eastman Chemical (NYSE:EMN) was downgraded by JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report issued on Monday, Price Targets.com reports. They presently have a $110.00 price target on the basic materials company’s stock, down from their previous price target of $130.00. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 5.74% from the company’s previous close.

Several other research firms have also recently commented on EMN. Bank of America raised shares of Eastman Chemical from a “neutral” rating to a “buy” rating and set a $140.00 target price on the stock in a research report on Thursday, August 5th. TheStreet lowered shares of Eastman Chemical from a “b-” rating to a “c+” rating in a research note on Monday, August 23rd. Royal Bank of Canada restated a “sector perform” rating and set a $109.44 price target (down previously from $119.00) on shares of Eastman Chemical in a research note on Tuesday, July 27th. Finally, KeyCorp decreased their price target on shares of Eastman Chemical from $137.00 to $119.00 and set an “overweight” rating for the company in a research note on Monday, October 11th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $128.86. Read more …

 

 


Lockheed Martin (NYSE:LMT) was downgraded by equities research analysts at Bank of America from a “buy” rating to a “neutral” rating in a report released on Monday, The Fly reports.

Several other research firms have also recently commented on LMT. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Lockheed Martin in a report on Friday, September 10th. Wells Fargo & Company lowered their price objective on Lockheed Martin from $385.00 to $340.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 27th. The Goldman Sachs Group lowered Lockheed Martin from a “buy” rating to a “neutral” rating and set a $402.00 price objective for the company. in a research report on Thursday, September 23rd. UBS Group lowered their price objective on Lockheed Martin from $425.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 27th. Finally, Robert W. Baird lowered their price objective on Lockheed Martin from $394.00 to $376.00 and set a “neutral” rating for the company in a research report on Wednesday, October 27th. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Lockheed Martin presently has a consensus rating of “Hold” and a consensus target price of $385.17. Read more …

 


Stanley Black & Decker (NYSE:SWK) was downgraded by stock analysts at Bank of America from a “neutral” rating to an “underperform” rating in a report issued on Monday, PriceTargets.com reports. They presently have a $170.00 price target on the industrial products company’s stock, down from their prior price target of $230.00. Bank of America‘s target price would suggest a potential downside of 3.99% from the company’s previous close.

A number of other research firms have also weighed in on SWK. Wells Fargo & Company lowered their target price on shares of Stanley Black & Decker from $227.00 to $219.00 and set an “overweight” rating on the stock in a report on Friday. Morgan Stanley lowered their target price on shares of Stanley Black & Decker from $234.00 to $215.00 and set an “overweight” rating on the stock in a report on Thursday, October 7th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Stanley Black & Decker from $241.00 to $238.00 and set a “buy” rating on the stock in a report on Wednesday, July 14th. Finally, Vertical Research started coverage on shares of Stanley Black & Decker in a report on Friday, October 8th. They issued a “buy” rating and a $227.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $214.36. Read more …

 


WestRock (NYSE:WRK) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued on Monday, Analyst Ratings Network reports. They presently have a $54.00 price target on the basic materials company’s stock, down from their previous price target of $84.00. Jefferies Financial Group’s price objective would suggest a potential upside of 12.27% from the stock’s current price.

Other equities analysts have also issued reports about the company. Wells Fargo & Company reduced their price objective on WestRock from $71.00 to $65.00 and set an “overweight” rating on the stock in a research note on Friday, October 8th. Truist started coverage on WestRock in a research note on Wednesday, October 13th. They issued a “hold” rating and a $47.00 price objective on the stock. KeyCorp reduced their price objective on WestRock from $49.00 to $45.00 and set an “underweight” rating on the stock in a research note on Friday, August 6th. Zacks Investment Research lowered WestRock from a “buy” rating to a “hold” rating and set a $53.00 price objective on the stock. in a research note on Friday, July 16th. Finally, Truist Securities started coverage on WestRock in a research note on Wednesday, October 13th. They issued a “hold” rating and a $47.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $55.42. Read more …

 

 


The Clorox (NYSE:CLX) was downgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a note issued to investors on Tuesday, The Fly reports. They presently have a $147.00 price objective on the stock, down from their prior price objective of $171.00. JPMorgan Chase & Co.‘s target price points to a potential downside of 10.04% from the company’s current price.

A number of other brokerages have also recently weighed in on CLX. Credit Suisse Group lowered their price target on The Clorox from $175.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 4th. Deutsche Bank Aktiengesellschaft boosted their price objective on The Clorox from $153.00 to $156.00 and gave the stock a “hold” rating in a research note on Wednesday, October 20th. UBS Group reduced their price objective on The Clorox from $166.00 to $154.00 and set a “sell” rating on the stock in a research note on Wednesday, August 4th. They noted that the move was a valuation call. Wells Fargo & Company reduced their price objective on The Clorox from $170.00 to $155.00 and set an “underweight” rating on the stock in a research note on Wednesday, August 4th. Finally, Royal Bank of Canada reduced their price objective on The Clorox from $200.00 to $176.00 and set a “sector perform” rating on the stock in a research note on Wednesday, August 4th. Six equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, The Clorox has a consensus rating of “Hold” and an average price target of $179.78. Read more …

 

No comments:

Post a Comment